ClinicalTrials.gg
RecruitingNCT06817876Updated Apr 15, 2026

Connecting Caregivers With Community Services: The Care Buddy Platform

An interventional study of Care Buddy in Dementia, sponsored by Duke-NUS Graduate Medical School. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Duke-NUS Graduate Medical School · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Dementia with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Dementia · Singapore.

Planned enrollment
12th of 22
210 · median 225
Started
2025
with 2 others
No phase
14 of 25
6 open now
Registered
19th of 25
by date
Lead sponsor
5 of 25
Duke-NUS Graduate Medical School

Among the 25 studies in Dementia with a site in Singapore, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 14 with no phase, and was the 19th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

7 of the 25 studies in Dementia with a site in Singapore are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Dementia with a site in Singapore, or all of them as a file.
02

Study summary

The study aims to develop a mobile-app (Care Buddy) which will be a one-stop integrated source of information and technology-based solutions for caregivers of people with dementia (PWDs). Study aims to bring caregivers into closer partnerships with the wider ecosystem (e.g., healthcare practitioners, community services, peer support, and care service providers) which will ultimately improve outcomes for both PWDs and their caregivers.

Read the detailed description

This is a 5-year study with various stages: 1) proof-of-concept stage to design and develop the Care buddy intervention, 2) proof-of-value stage to assess the feasibility, acceptability and satisfaction with the Care buddy intervention among informal caregivers of PWDs, 3) test-bedding stage to assess the efficacy and cost-effectiveness of the Care buddy intervention versus usual care among informal caregivers of PWDs with help of a multi-centre 2-arm RCT and 4) deployment stage to scale up the intervention at multiple centres across Singapore, monitor its adoption and outcomes and assess any organizational and individual barriers to adoption.

By the end of the proposed five-year project, investigators aim to develop and evaluate the technology as well as achieve widespread adoption among caregivers of PWDs. Investigators want to enable easy access to information, provide decisional and social support, improve the reach and uptake of existing community service providers, and assist with coordination among multiple informal and professional caregivers through the journey of dementia caregiving and into the bereavement phase.

03

Conditions studied

  • Dementia

Browse trials for

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The inclusion criteria for patients are

    1. Singaporean/Permanent residents
    2. Age 21 years of age or older
    3. Main person or one of the main persons involved in making decisions regarding treatment patient receives or responsible for ensuring the well-being of the patient
    4. An active primary caregiver for at least 6 months, and planning to remain the primary caregiver for the next 2 years
    5. Is a family member of the patient with dementia
    6. Can read and write in English
    7. Accessible by telephone to schedule interviews
    8. Has familiarity with use of technology (e.g., computers, tablets, or internet) and is able to complete surveys, forms using digital technology
    9. Intact cognition determined through the Abbreviated Mental Test (AMT) for those who are ≥ 65 years old.
    10. Caregivers who score >=9 on the 6-item Zarit Burden scale

Exclusion criteria

Exclusion Criteria:

  • Caregivers of patients staying in nursing home or other long-term care facility with no intention of being discharged will not be eligible however, if the patient is admitted to respite care for short/long term duration after being recruited, caregivers can continue to participate.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    CareBuddy

    Caregivers of person with dementia who will be randomized in this arm will have access to the CareBuddy mobile app on their phone. They will be using this app for 1 year and will be followed up every 2 months.

    Device: Care Buddy

  • No intervention
    Usual care

    Caregivers of person with dementia who will be randomized in this arm will continue usual care for their loved one. They will be enrolled for 1 year and will be followed up every 2 months.

Interventions

  • DeviceCare Buddy

    Care Buddy mobile intervention will be a one-stop solution for caregivers of dementia patients and help them in their care-giving journey by providing them solutions to manage behavioural problems, physical conditions of their loved one. The app will be multi-component and will provide tools for the caregiver to manage their stress and burden. It will provide information on dementia, list of service providers, information on grief, financial support. This app will provide a platform for all enrolled caregivers to chat with each other and provide social support.

06

What researchers measure

Primary outcomes

  1. Caregiver Psychological well-being

    Flourish - range - 8 - 56, high score represents a person with many psychological resources and strengths

    Time frame: 1 year from data collection

  2. Caregiver social scale

    Friendship scale - The score range is 0-24. A high score represents social connectedness and a score of "0" complete social isolation

    Time frame: 1 year from data collection

  3. Caregiver Dementia Knowledge

    The Dementia Knowledge Assessment Tool - range - 0-21. High score equals to higher knowledge of dementia.

    Time frame: 1 year from data collection

  4. Caregiver Impact

    Revised Memory \& Behavior Problem checklist - range - 0-96 Higher score indicates increased impact.

    Time frame: 1 year from data collection

  5. Caregiver Burden

    Zarit Burden scale - range 0-88. 0 - 21 little or no burden, 21 - 40 mild to moderate burden, 41 - 60 moderate to severe burden, 61 - 88 severe burden \>34 - clinically significant burden.

    Time frame: 1 year from data collection

  6. Caregiver Stress

    Perceived Stress Scale: Scoring: PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items.

    Time frame: 1 year from data collection

Other outcomes

  1. Health care costs

    Health care costs, hospitalizations and emergency room visits for caregivers and PWDs will be obtained from patient billing data.

    Time frame: 1 year from data collection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2026, 13 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 13 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 10, 2025
StartActual
Apr 1, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06817876
Lead sponsor
Duke-NUS Graduate Medical School
Collaborators
Agency for Science, Technology and Research (A*STAR), Khoo Teck Puat Hospital
Responsible party
Chetna Malhotra (Associate Professor, Duke-NUS Graduate Medical School) — Principal investigator
First posted
Feb 10, 2025
Start date
Apr 1, 2025
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Chetna Malhotra, MD, MPH
Contact
chetna.malhotra@duke-nus.edu.sg
+65 65165692

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion